Trial Profile
Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 11 Apr 2022 Status changed from active, no longer recruiting to completed.
- 05 Mar 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.
- 05 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 May 2023.